Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

DRUG

Bright Minds Biosciences Inc

May 01 • 04:00PM ET

1.04

Dollar change +0.07
Percentage change 7.77	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: PSIL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.31	Insider Own	36.66%	Shs Outstand	3.77M	Perf Week	-4.59%
Market Cap	4.49M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.74M	Perf Month	-24.64%
Income	-4.98M	PEG	-	EPS next Q	-	Inst Own	4.08%	Short Float	2.76%	Perf Quarter	-51.85%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	3.12	Perf Half Y	-21.80%
Book/sh	1.02	P/B	1.01	EPS next Y	-	ROA	-72.42%	Short Interest	0.08M	Perf Year	-65.99%
Cash/sh	1.19	P/C	0.88	EPS next 5Y	-	ROE	-78.58%	52W Range	0.93 - 6.44	Perf YTD	-27.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-137.36%	ROI	-108.80%	52W High	-83.85%	Beta	1.17
Dividend TTM	-	Quick Ratio	8.01	Sales past 5Y	0.00%	Gross Margin	-	52W Low	11.83%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	8.01	EPS Y/Y TTM	63.68%	Oper. Margin	0.00%	RSI (14)	36.99	Volatility	10.96% 9.62%
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	45.46
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	32.90%	Payout	-	Rel Volume	1.90	Prev Close	0.96
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	24.29K	Price	1.04
SMA20	-11.00%	SMA50	-24.60%	SMA200	-42.98%	Trades		Volume	46,245	Change	7.77%

Dec-06-23 05:08PM	Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management (PR Newswire) +5.53%
Aug-08-23 06:50AM	Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) +29.50%
Jul-20-23 06:50AM	Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 (GlobeNewswire) -16.38%
Jul-11-23 06:50AM	Bright Minds Announces Effective Date of Share Consolidation (GlobeNewswire)
Jun-22-23 06:50AM	Bright Minds Announces Proposed Share Consolidation (GlobeNewswire) +5.33%
06:50AM	Loading…
Apr-19-23 06:50AM	Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202 (GlobeNewswire) +26.08%
Apr-10-23 06:50AM	Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research (GlobeNewswire)
Feb-27-23 06:50AM	Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 (GlobeNewswire) -10.54%
Feb-17-23 06:50AM	Bright Minds Biosciences Announces Non-Executive Director Appointment (GlobeNewswire)
Feb-08-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements (GlobeNewswire)
Jan-27-23 04:05PM	Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (GlobeNewswire)
Jan-09-23 04:05PM	Bright Minds Biosciences Announces Resignation of Board Member (GlobeNewswire) -7.46%
Dec-02-22 07:07PM	Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement (GlobeNewswire)
Nov-28-22 06:50AM	Bright Minds Biosciences Announces Non-Brokered Private Placement (GlobeNewswire) +10.78%
Nov-23-22 11:35AM	Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
06:50AM	Loading…
Sep-07-22 06:50AM	Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors (GlobeNewswire)
Aug-31-22 06:50AM	Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome (GlobeNewswire) -15.42%
Aug-30-22 03:35PM	Bright Minds Biosciences Announces Closing of $4 Million Unit Offering (GlobeNewswire) -23.05%
Aug-23-22 09:07PM	Bright Minds Announces Pricing of Overnight Marketed Offering of Units (GlobeNewswire) -38.43%
Aug-22-22 07:05PM	Bright Minds Announces Overnight Marketed Offering of Units (GlobeNewswire) +72.80%
Aug-18-22 03:34PM	Bright Minds Biosciences Comments on Recent Trading Activity (GlobeNewswire) +121.43%
Jun-27-22 06:50AM	Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization (GlobeNewswire)
May-12-22 06:50AM	Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome (GlobeNewswire)
May-02-22 06:50AM	Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties (GlobeNewswire)
Apr-19-22 06:50AM	Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders (GlobeNewswire) +8.40%
Mar-14-22 06:50AM	Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial (GlobeNewswire)
Mar-08-22 07:30AM	Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Jan-04-22 04:05PM	Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference (GlobeNewswire)
Dec-15-21 05:13PM	Canadian Securities Exchange's November 2021 Performance Includes Strong Listings Growth and New Financing Milestone (Newsfile)
Dec-06-21 06:50AM	Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference (GlobeNewswire)
07:30AM	Loading…
Nov-30-21 07:30AM	Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases (GlobeNewswire) -8.35%

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DRUG

Bright Minds Biosciences Inc

Upgrade your FINVIZ experience